Valeant Pharmaceuticals International Inc (VRX): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Valeant Pharmaceuticals International ( VRX) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 2.1%. By the end of trading, Valeant Pharmaceuticals International rose $3.87 (3.0%) to $132.17 on average volume. Throughout the day, 1,382,771 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1,117,100 shares. The stock ranged in a price between $127.15-$132.89 after having opened the day at $128.13 as compared to the previous trading day's close of $128.30. Other companies within the Health Care sector that increased today were: Intercept Pharmaceuticals ( ICPT), up 281.1%, Galectin Therapeutics ( GALT), up 59.3%, Conatus Pharmaceuticals ( CNAT), up 57.0% and Sangamo BioSciences ( SGMO), up 38.3%.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $41.7 billion and is part of the drugs industry. Shares are up 9.3% year to date as of the close of trading on Wednesday. Currently there are 8 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk.

On the negative front, Mast Therapeutics ( MSTX), down 25.6%, AEterna Zentaris ( AEZS), down 18.5%, AMAG Pharmaceuticals ( AMAG), down 14.9% and IMRIS ( IMRS), down 10.5% , were all laggards within the health care sector with Jazz Pharmaceuticals ( JAZZ) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Jim Cramer Just Spoke to Larry Kudlow About the China Trade Negotiations

Jim Cramer Just Spoke to Larry Kudlow About the China Trade Negotiations

Stocks Rise, Facebook Ignites a Nasdaq Rally

Stocks Rise, Facebook Ignites a Nasdaq Rally

Short Seller Chanos Slams Tesla's Musk, Accuses Him of 'Incinerating' Capital

Short Seller Chanos Slams Tesla's Musk, Accuses Him of 'Incinerating' Capital

AMD Shares Explode After Solid Q1, Robust Outlook That Defies Chip Sector Gloom

AMD Shares Explode After Solid Q1, Robust Outlook That Defies Chip Sector Gloom

Facebook Stock Set for Biggest Gain in Two Years After Q1 Earnings Top Forecasts

Facebook Stock Set for Biggest Gain in Two Years After Q1 Earnings Top Forecasts